509147-79-9

Usage

Uses

Used in Pharmaceutical Synthesis:
Tert-butyl 4-(2-Methoxyethyl)piperidine-1-carboxylate is utilized as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of novel compounds with therapeutic potential.
Used in Agrochemical Synthesis:
tert-butyl 4-(2-Methoxyethyl)piperidine-1-carboxylate also serves as an intermediate in the synthesis of agrochemicals, where its unique structure aids in the creation of new compounds designed to address various agricultural needs.
Used in Medicinal Chemistry Research:
Tert-butyl 4-(2-Methoxyethyl)piperidine-1-carboxylate is employed by researchers and chemists in the field of medicinal chemistry. It is used as a key component in the design and synthesis of innovative compounds that hold promise for treating a range of medical conditions.

Upstream product

• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 70724-70-8 4-(2-methoxyethyl)piperidine 
• 868849-54-1 4-(2-methoxyethyl)piperidine hydrochloride 

Relevant academic research and scientific papers

2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

Compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS

Thienopyrimidines of formula (Ia) or (Ib): wherein R1, R2, R3, are as defined in the claims.

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

Benzimidazolidinone derivatives as muscarinic agents

Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.